MarketCap
Facebook
X
Telegram
Navidea Biopharmaceuticals Book Value | NAVB
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.14 M | 625 K | 2.05 M | -881 K | 2.41 M | 12 M | -67.7 M | -53.8 M | -29.8 M | -4.01 M | -1.41 M | 21.1 M | 4.13 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.1 M | -67.7 M | -9.49 M |
Quarterly Book Value Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.98 M | -787 K | -9.55 M | -8.14 M | -4.67 M | -4.24 M | -2.11 M | 625 K | 4.13 M | 6.44 M | 5.01 M | 2.05 M | 901 K | 1.83 M | -1.09 M | -881 K | -92.7 K | 2.93 M | 94.6 K | 2.41 M | 2.01 M | 2.79 M | 4.95 M | 12 M | 16 M | 17.3 M | 22.4 M | -67.7 M | -63.8 M | -63.9 M | -57.2 M | -53.8 M | -51.8 M | -44.6 M | -35.4 M | -29.8 M | -31.3 M | -23.8 M | -14.6 M | -4.01 M | 8.86 M | -1.83 M | -2.72 M | -1.41 M | 2.75 M | 9.93 M | 14.7 M | 21.1 M | 28.5 M | 6.08 M | 21.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.5 M | -67.7 M | -7.16 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
317 M | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Allakos
ALLK
|
78.8 M | - | - | $ 28.6 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
610 M | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
112 M | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
112 M | - | - | $ 401 M | USA |
 |
Rezolute
RZLT
|
101 M | $ 3.94 | 1.87 % | $ 299 M | USA |
 |
Evelo Biosciences
EVLO
|
-4.99 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
23.3 M | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
177 M | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
52.4 M | - | - | $ 384 M | Britain |
 |
Genocea Biosciences
GNCA
|
27.1 M | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
3.13 B | $ 3.63 | 3.93 % | $ 795 M | Britain |
|
Amryt Pharma plc
AMYT
|
357 M | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
35.4 M | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
142 M | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
257 M | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
50.5 M | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
65 M | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
134 B | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
-46.8 M | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
159 M | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
6.08 M | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
Фармсинтез
LIFE
|
29.8 B | - | - | - |  Russia |
 |
Cellectar Biosciences
CLRB
|
9.92 M | $ 2.08 | 0.48 % | $ 5.43 M | USA |
 |
IGM Biosciences
IGMS
|
48.2 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-6.6 M | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
159 M | - | - | $ 123 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Karuna Therapeutics
KRTX
|
1.25 B | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
6.33 M | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
992 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
302 M | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
648 M | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
122 M | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
148 M | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
5.46 M | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
405 M | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
61.2 M | $ 11.8 | 8.21 % | $ 932 M | USA |
|
Champions Oncology
CSBR
|
4.07 M | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
76.6 M | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
26.4 M | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
16 M | $ 1.72 | 2.38 % | $ 13.8 M | USA |